BPC-157 vs TB-500
BPC-157 is not FDA-approved and rated 2/5 for evidence; TB-500 is not FDA-approved and rated 2/5. They have a similar amount of human evidence. Both are banned in sport by WADA. Both are used for recovery & repair goals.
Often used together: The popular 'Wolverine' pairing — BPC-157 for local repair, TB-500 for systemic recovery.
| Compare |  BPC-157The most-discussed healing peptide, built on a stomach-protein fragment. |  TB-500Synthetic fragment of thymosin beta-4, used for whole-body recovery. |
|---|---|---|
| Category | Recovery & Repair | Recovery & Repair |
| Evidence | 2/5Dozens of rodent studies; only tiny human pilot data (e.g. knee pain retrospective, IV safety pilot). | 2/5Full-length Tβ4 has some human trials (eye, wound); TB-500 fragment is mostly animal and anecdotal. |
| FDA status | Not FDA-approved for any use | Not FDA-approved |
| WADA (sport) | Banned | Banned |
| Also known as | Body Protection Compound-157, Bepecin, PL 14736 | Thymosin Beta-4 fragment, Tβ4 (Ac-SDKP / LKKTETQ region) |
| How it works | Appears to up-regulate growth-factor receptors (VEGFR2, growth hormone receptor), promote new blood vessel formation (angiogenesis), and modulate nitric-oxide signaling. Exact human pharmacology is not established. | Binds actin, helping cells migrate to injured tissue; promotes angiogenesis and reduces inflammation in models. Full-length thymosin beta-4 has been studied in dry eye and wound healing trials; the TB-500 fragment itself has little human data. |
| Half-life | Short (hours); effects thought to be local + signaling driven | Not well characterized; dosed twice weekly by convention |
| Commonly reported doses |
|
|
| Route | Subcutaneous, near injury site | Subcutaneous |
| Good once mixed | ~28 days in the fridge | ~28 days in the fridge |
| Top side effects |
|
|
| Lowest price per mg | $2.40 (10 mg vial, 40% off) | $2.40 (10 mg vial, 40% off) |
| Latest lab purity | 99.61% (lot BP0002) | 99.51% (lot TB0002) |
Want a third? Add another peptide. Doses are commonly reported ranges, not recommendations.